Our SmartGut provides valuable information to healthcare providers and patients. The data we have gathered since the launch of SmartGut has been invaluable in helping us more fully understand the human microbiome in the context of gut conditions.
SAN FRANCISCO (PRWEB) February 06, 2018
uBiome, the leader in microbial genomics, has launched a new research study to better understand the link between the human gut microbiome and diet, lifestyle, and weight management in patients who have used its SmartGut™ medical test, available through healthcare providers.
“Our SmartGut provides valuable information to healthcare providers and patients. The data we have gathered since the launch of SmartGut has been invaluable in helping us more fully understand the human microbiome in the context of gut conditions,” said Zachary Apte, PhD, co-founder and CTO at uBiome. “We’re excited to see the results of this research as it relates to weight management and other lifestyle factors within this cohort.”
SmartGut, which must be prescribed by a healthcare provider, uses precision sequencing™ technology to identify microbes in a patient’s gut that might be affecting his or her gut conditions. SmartGut helps doctors better understand common conditions related to the gut, such as bloating, constipation, diarrhea and other symptoms of irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease.
SmartGut samples are processed in uBiome’s CLIA-licensed and CAP-accredited laboratory in San Francisco, California. The College of American Pathologists, with more than 18,000 members, is the world’s leading organization of board-certified pathologists. Its goal is to serve patients, physicians, and the public by encouraging, promoting, and supporting excellence in pathology and laboratory medicine.
SmartGut is available through healthcare providers in the United States and Canada. SmartGut users can choose to participate in this research if desired, but participation is not mandatory in order to receive SmartGut test results.
For more information on SmartGut, eligibility criteria for this research study, and how to request a kit, please visit uBiome’s study page.
uBiome is the leading microbial genomics company. Funded by Y Combinator, Andreessen Horowitz, and other leading investors, uBiome pioneered the field of microbial genomics starting in 2012. uBiome’s mission is to transform the science of the microbiome into useful products and services that improve people’s lives.